FARMINGDALE, N.Y. (Reuters) - Biotech company Enzo Biochem Inc.
(NYSE:ENZ - news) said on Monday a patient participating in a
Phase I study produced new immunity cells to combat the virus
that causes AIDS web-.
The tests show that after nine-and-one-half months, Enzo-
engineered cells have successfully engrafted in the patient's
bone marrow and were spawning new cells designed to fight HIV.
The company said it is preparing for a Phase II trial of the
HGTV-43 medicine product and has already begun negotiating with
several hospitals at which broader studies would be conducted.
Enzo is compiling and analyzing data from the remaining five
patients in the trial, and said that the data is highly
encouraging, though limited and must await further study.